Organisation paid for research Program year 2021 Source: CMS Open Payments

Vanderbilt Univ Medical Ctr

Neither a doctor nor a teaching hospital

Research payments

$162,347

23 payments

Through program year 2021, Vanderbilt Univ Medical Ctr is reported as receiving $162,347 in research payments, across 23 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$1,032	2
2020	Research	$59,516	4
2019	Research	$101,799	17

Breakdown

Who paid Research payments · program years 2019–2021

Astellas Pharma Global Development $162,347 23 payments

Studies the money was for Research payments · program years 2019–2021

Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HF with Preserved EF $58,792 4 payments
Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in Heart Failure With Preserved Ejection Fraction $57,644 2 payments
The Role of enzalutamide in Prostate Cancer Radiation Therapy $21,824 1 payment
A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation. $14,820 7 payments
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study $4,824 4 payments
A Phase 12 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia. $2,895 2 payments
A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. $1,032 2 payments
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation $516 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.